ClinicalTrials.gg
CompletedNCT03278470Updated Aug 17, 2018

A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject

A Phase 1 interventional study of HL237 and Placebo Oral Tablet in Rheumatoid Arthritis, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-17.

Sponsored by Hanlim Pharm. Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of — 9 open to participants now, 15 under way, 2 of them phase 3. Arthritis, Rheumatoid · Korea, Republic of.

Enrollment
135th of 155
57 · median 300
Started
2017
with 6 others
Phase 1
20 of 188
none open now
Registered
149th of 188
by date

Among the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, this one is the 135th largest by enrollment of the 155 interventional ones that give a count, is one of 7 that started in 2017, is one of 20 in phase 1, and was the 149th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, or all of them as a file.
02

Study summary

HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic structure of biguanide in metformin, an existing diabetes drug.

The immune modulating activity of HL237 was demonstrated in animal model. HL237 is a STAT3 inhibitor and STAT3 is well known for an important regulator inhibiting Th17 cells and activating Treg cells.

Therefore, when STAT3 activity is inhibited, it is expected to be able to treat autoimmune diseases such as rheumatoid arthritis.

This is the first clinical trial to be conducted for the development of HL237 and this clinical trial is for determining the maximum oral dose of HL237 and assessing safety, tolerability, and pharmacokinetic characteristics for each dose group.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A healthy adult male aged 20 years or older and 45 years old at the time of the screening test
  • Those who weigh more than 55kg but weigh less than ± 20% of ideal body weight
  • Proper during the clinical trial period
  • After hearing the detailed explanation of the clinical trial, those who decide to participate voluntarily and write agreement

Exclusion criteria

Exclusion Criteria:

  • , a person with a history of neurological, psychiatric, malignant, cardiovascular, respiratory, kidney, endocrine, hematologic, digestive or central disease
  • a person with a history of gastrointestinal disorders that may affect the absorption of pharmaceuticals for clinical trials (Crohn's disease, ulcers, etc.) or gastrointestinal surgery (except for simple cecal surgery or hernia surgery)
  • a person with a history of or clinically significant hypersensitivity to the clinical trial drug or additives
  • a person judged to be inappropriate for the subject by health screening (history of disease, physical examination, vital signs, , laboratory test, etc.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    HL237 50mg

    take oral tablet once

    Drug: HL237 · Drug: Placebo Oral Tablet

  • Experimental
    HL237 100mg

    take oral tablet once

    Drug: HL237 · Drug: Placebo Oral Tablet

  • Experimental
    HL237 200mg

    take oral tablet once

    Drug: HL237 · Drug: Placebo Oral Tablet

  • Experimental
    HL237 400mg

    take oral tablet once

    Drug: HL237 · Drug: Placebo Oral Tablet

  • Experimental
    HL237 800mg

    take oral tablet once

    Drug: HL237 · Drug: Placebo Oral Tablet

  • Experimental
    HL237 1200mg

    take oral tablet once

    Drug: HL237 · Drug: Placebo Oral Tablet

  • Experimental
    HL237 1600mg

    take oral tablet once

    Drug: HL237 · Drug: Placebo Oral Tablet

Interventions

  • DrugHL237

    Experimental

  • DrugPlacebo Oral Tablet

    placebo with same properties except for active ingredient

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration [Cmax]

    maximum serum concentration after the drug has been administrated

    Time frame: 3days after administration

  2. Area Under the Curve [AUC]

    Time frame: 3days after administration

  3. half life [t1/2]

    Time frame: 3days after administration

Secondary outcomes

  1. Number of participants with treatment-related adverse events

    Time frame: 14days after administration

07

Study locations

1 site
  • The catholic university of korea seoul ST. mary's hospital
    Soeul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Mar 2018, 8 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 8 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2017
First posted
Sep 11, 2017
StartActual
Jun 26, 2017
Primary completionActual
Mar 19, 2018
CompletionActual
Mar 19, 2018
Last update
Aug 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03278470
Responsible party
Sponsor
First posted
Sep 11, 2017
Start date
Jun 26, 2017
Primary completion
Mar 19, 2018
Completion
Mar 19, 2018
Last update
Aug 17, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HL237

Start the discussion